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Abstract
Background: The risk factors for peripheral artery disease (PAD) are more common in Indigenous than non-
Indigenous Australians, however the presentation and outcome of PAD in Indigenous Australians has not been
previously investigated. The aim of this prospective cohort study was to compare the presenting characteristics and
clinical outcome of Indigenous and non-Indigenous Australians with PAD.
Methods: PAD patients were prospectively recruited and followed-up since 2003 from an outpatient vascular clinic
in Townsville, Australia. Presenting symptoms and risk factors in Indigenous and non-Indigenous patients were
compared using Pearson’s χ2 test and Mann Whitney U test. Kaplan Meier survival analysis and Cox proportional
hazard analysis were used to compare the incidence of myocardial infarction (MI), stroke or death (major
cardiovascular events) among Indigenous and non-Indigenous patients.
Results: Four hundred and one PAD patients were recruited, of which 16 were Indigenous and 385 were non-
Indigenous Australians. Indigenous Australians were younger at entry (median age 63.3 [54.7–67.8] vs 69.6 [63.3–75.
4]), more commonly current smokers (56.3% vs 31.4%), and more frequently had insulin-treated diabetes (18.8% vs
5.2%). During a median follow-up of 2.5 years, five and 45 major cardiovascular events were recorded amongst
Indigenous and non-Indigenous Australians, respectively. Indigenous Australians were at ~ 5-fold greater risk of
major cardiovascular events (adjusted hazard ratio 4.72 [95% confidence intervals 1.41–15.78], p = 0.012) compared
to non-Indigenous Australians.
Conclusions: These findings suggest that Indigenous Australians with PAD present at a younger age, have higher
rates of smoking and insulin-treated diabetes, and poorer clinical outcomes compared to non-Indigenous
Australians.
Background
Peripheral artery disease (PAD) refers to a range of sten-
osing and aneurysmal disorders of the extra-coronary
and extra-cerebral arteries [1]. Examples of common
PAD pathologies include lower limb occlusive disease,
abdominal aortic aneurysm (AAA), and carotid artery
stenosis. The burden of PAD is significant. Lower limb
occlusive disease is estimated to affect ~ 200 million
people worldwide, [2] and ~ 20 million people are esti-
mated to have AAA [3]. Moreover, the prevalence of
PAD is expected to double by 2040 due to population
aging [4]. Despite current best care, PAD patients are at
approximately three times higher risk of cardiovascular
and all-cause mortality, compared to those without PAD
[5]. Mortality attributed to PAD has been estimated to
be higher in Australasia than in any other part of the
world (3.89 per 100, 000 [95% CI 2.2–6.9]) [6]. The rea-
sons for this have not been clearly demonstrated al-
though one possible explanation is the high incidence
and complication rates of PAD amongst sub-sets of the
Australasian population. Indigenous Australians could
contribute to such a high risk sub-set since they have
previously been reported to have an excess of risk factors
for PAD and its complications [7].
Indigenous Australians (Aboriginal and Torres Strait
Islanders) have been reported to have a life expectancy
of approximately 17 years less than non-Indigenous Aus-
tralians, and a burden of disease 2.5 fold higher [8].
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Non-communicable diseases represent 70% of the health
gap, of which cardiovascular diseases are the leading
contributor, followed by diabetes [9]. Despite awareness
of the excess burden of cardiovascular diseases in Indi-
genous Australians, it has been difficult to establish
health priorities and policy for many vascular conditions.
A major reason for this is the lack of reliable clinical
data, as currently most data available stems from admin-
istrative government data, which does not capture the
complete spectrum of diseases and associated risk fac-
tors. This is particularly true for medical conditions
which require specific investigation based diagnosis such
as PAD.
Indigenous Australians have previously been reported
to have a 3-fold higher risk of developing PAD (adjusted
for age, diabetes duration, and smoking status) [10].
They also have more frequent risk factors for PAD com-
pared to non-Indigenous Australians, including diabetes
(5–10 fold higher), [11] hypertension (3–8 fold higher),
[11] and smoking (5-fold higher) [7]. Moreover, it has
been estimated that the risk of major amputations
(below or above the knee) in 25–49 year olds is approxi-
mately 40-fold higher in Indigenous compared to non-
Indigenous Australians, attributable to the earlier onset
of underlying conditions such as diabetes [7, 12]. There
is, however, little understanding of the presenting char-
acteristics and outcome of PAD in this population.
Therefore, the aim of this prospective cohort study was
to compare the presenting characteristics and the risk of
major cardiovascular events (myocardial infarction [MI],
stroke or death) in Indigenous and non-Indigenous Aus-




This was a prospective cohort study of PAD partici-
pants recruited from an outpatient clinic in Towns-
ville Hospital (Ethics [HREC/13/QTHS/125; SSA/13/
QTHS/203; HREC/14/QTHS/203; H6028 & H5537]
[13, 14]. A 5-member Indigenous reference committee
was consulted for approval of the research. The re-
cruitment period for this cohort was between May
2003 and February 2016. Patients who provided writ-
ten informed consent and met the following eligibility
criteria were included: diagnosis of PAD by a vascular
specialist as previously described, [13] including any
of the following presentations: intermittent claudica-
tion, critical limb ischemia, asymptomatic or symp-
tomatic carotid stenosis, and aortic or peripheral
aneurysms. Patients who identified themselves as
Aboriginal and/or Torres Strait Islanders were consid-
ered Indigenous. Patients who did not identify as In-
digenous were considered non-Indigenous.
Measures
Clinical characteristics collected for each participant in-
cluded: presenting complaint, age, sex, diabetes, hyper-
tension, smoking history, dyslipidaemia, renal function
(estimated glomerular filtration rate [eGFR]), ischaemic
heart disease (IHD), history of stroke, and current medi-
cations. Hypertension and diabetes were defined by his-
tory or treatment for these conditions. Cigarette
smoking classification was based on smoking history,
and defined as current smoker (smoked within the last
month), previous smoker or never smoked. IHD was de-
fined by a history of myocardial infarction, angina or
coronary revascularization. Serum creatinine was mea-
sured using a spectrophotometry method in a pathology
laboratory as previously described [1]. eGFR was calcu-
lated using the Chronic Kidney Disease Epidemiology
Collaboration formula, as this has previously been
shown to best predict complications [1]. Abdominal aor-
tic aneurysm (AAA) was defined as an orthogonal infra-
renal aortic diameter of at least 30 mm on ultrasound or
computed tomography angiography [13, 14]. A signifi-
cant carotid artery stenosis was defined as ≥50% using
Australian Society for Ultrasound in Medicine criteria
[13, 14]. Current prescriptions for aspirin, other anti-
platelet agents, warfarin, beta-blockers, calcium channel
blockers, angiotensin pathway inhibitors, metformin, in-
sulin, frusemide and statins were recorded. Follow-up
data was retrieved from out-patient visits, hospital chart
reviews, linked data and /or inpatient admissions as pre-
viously described [13, 14]. The primary outcome was to
evaluate the differences in the combined incidence of
major cardiovascular events (MI, stroke or death) be-
tween Indigenous and non-Indigenous Australians with
PAD. The diagnoses of MI and stroke were made by
Royal Australasian College of Physicians accredited
physician in accordance with international guidelines
[15, 16]. Death was defined to include deaths from all
causes. Linked data were based on International Classifi-
cation of Diseases (ICD)-10 coding for MI (I21.0-I22.9)
and stroke (I60.0-I64.0). Patients were censored at the
first major event, or at the date of last review or linked
data request, if they did not experience an event.
Sample size calculation
The required sample size was estimated according to a
planned Cox regression analysis, examining the associ-
ation of Indigenous status with major cardiovascular
events. On the basis of previous PAD studies conducted
at The Townsville Hospital, the incidence of major car-
diovascular events was estimated to be 30% over 3 years,
[17] and the model was designed to include the follow-
ing variables: age, sex, IHD, diabetes, hypertension,
smoking and Indigenous status. It was therefore esti-
mated that approximately 230 patients in total would be
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needed to be included in order to attain 10 outcome
events per degree of freedom for each predictor variable
to be included in the Cox regression analysis [18].
Statistical analysis
The presenting symptoms and risk factors were
compared between Indigenous and non-Indigenous
patients using Pearson’s χ2 test and Mann Whitney
U test. The combined incidence of MI, stroke or
death in Indigenous and non-Indigenous groups was
assessed with Kaplan-Meier analysis with differences
compared using the log rank test. Multivariate Cox
proportional hazards analyses were undertaken to as-
sess the association between Indigenous status and
cardiovascular events, adjusting for relevant con-
founding risk factors and medications (hypertension,
current smoking, diabetes, IHD, age, critical limb is-
chemia, insulin, frusemide, angiotensin converting
enzyme [ACE] inhibitor, anti-platelet or anti-
coagulant prescription) across 3 different models.
The selection of variables to adjust for was based on
those which have been established as risk factors for
PAD outcome, or were found to be significantly dif-
ferent between Indigenous and non-Indigenous
patients. No violations of the proportional hazards
assumption were observed. All analyses were per-
formed using STATA version 14.1 (StataCorp, Col-
lege Station, Texas, USA), and SPSS version 20.0
(IBM SPSS Inc., Chicago, Illinois, USA).
Results
Participant characteristics
Four hundred and one patients with PAD were in-
cluded, of which 16 (4.0%) were Indigenous and 385
(96.0%) were non-Indigenous Australians. Indigen-
ous participants were younger at entry (median age
63.3 [54.7–67.8] vs 69.6 [63.3–75.4], p = 0.005),
were more likely to be current smokers (56.3% vs
31.4%, p = 0.041) and have insulin-treated diabetes
(18.8% vs 5.2%, p = 0.022). Indigenous participants
were also more likely to be prescribed frusemide for
heart failure (Table 1). A lower proportion of Indi-
genous Australians were prescribed a statin, al-
though this difference was not significant. There
were no significant differences in presenting com-
plaint at entry between Indigenous and non-
Indigenous Australians (Table 2).
Table 1 Demographic and risk factors of included PAD patients
Characteristics Indigenous (n = 16) Non-Indigenous (n = 385) p-value
Age (y) 63.3 (54.7–67.8) 69.6 (63.3–75.4) 0.005
Sex (% Males) 10 (62.5%) 293 (76.1%) 0.215
Diabetes mellitus 7 (43.8%) 103 (26.8%) 0.135
Smoker 0.041
Never 0 (0%) 82 (21.3%)
Current 9 (56.3%) 121 (31.4%)
Previous 7 (43.8%) 182 (47.3%)
Hypertension 15 (93.8%) 290 (75.3%) 0.091
IHD 10 (62.5%) 164 (42.6%) 0.116
Stroke 1 (6.3%) 38 (9.9%) 0.632
eGFR (mL/min/1.73m2) 79.0 (46.5–85.8) [2]a 78 (60.0–91.0) [93]a 0.416
Medications
Aspirin 11 (68.88%) 252 (65.5%) 0.786
Other antiplatelet 3 (18.8%) 66 (17.1%) 0.867
Frusemide 4 (25.0%) 28 (7.3%) 0.010
ACEI 10 (62.5%) 152 (39.5%) 0.066
Beta-Blocker 6 (37.5%) 115 (29.9%) 0.515
Calcium channel blocker 3 (18.8%) 115 (29.9%) 0.339
Metformin 4 (25.0%) 69 (17.9%) 0.472
Insulin 3 (18.8%) 20 (5.2%) 0.022
Statin 13 (81.3%) 273 (70.9%) 0.370
IHD ischaemic heart disease, eGFR estimated glomerular filtration rate, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker
aRepresents the number of missing data-points. Continuous data are presented as median [interquartile range] and were compared using Mann-Whitney U test.
Nominal data are presented as number (%) and were compared using Pearson’s χ2 test. P-values highlighted in bold indicate significant differences
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Association between indigenous ethnicity and major
cardiovascular events
Median (inter-quartile range) follow-up in Indigenous
patients and non-Indigenous patients was 2.5 (0.3–5.3)
and 2.5 (0.4–5.4) years, respectively (p = 0.973). In total,
five major cardiovascular events (MI, stroke, or death)
were recorded in Indigenous Australians, and 45 major
cardiovascular events were recorded in non-Indigenous
Australians. Kaplan Meier curves illustrating the cumu-
lative proportion of Indigenous and non-Indigenous pa-
tients who had major cardiovascular events are
presented in Fig. 1. Differences between both groups
were considered to be significant (log-rank test p = 0.
004). By unadjusted Cox proportional hazard analysis,
Indigenous Australians had a 3.59-fold higher risk of
major cardiovascular events during follow-up compared
to non-Indigenous Australians (p = 0.007; Table 3). By
multivariate Cox proportional hazard analysis, Indigen-
ous Australians were at ~ 5-fold greater risk of major
cardiovascular events (HR 4.72 [1.41–15.78], p = 0.012),
after adjusting for hypertension, current smoking, dia-
betes, IHD, age, critical limb ischemia, insulin, frusem-
ide, ACE inhibitor, anti-platelet or anti-coagulant
prescription (Table 3).
Discussion
To our knowledge, this is the first comparison of the
clinical presentation and outcome of PAD in Indigenous
and non-Indigenous Australians. The results of this pro-
spective cohort study suggest that Indigenous Austra-
lians present at a younger age with PAD, have more
frequent cardiovascular risk factors, and are at signifi-
cantly greater risk of developing major cardiovascular
events compared to non-Indigenous Australians.
In this cohort, Indigenous Australians were more
likely to have insulin-treated diabetes, which is re-
flective of the greater severity of diabetes in this
population [7]. Indigenous Australians were more
likely to be prescribed frusemide, which reflects the
greater burden of heart failure in this population as
previously identified [19]. In terms of outcome, Indi-
genous Australians were at approximately 5-fold
greater risk of developing cardiovascular events in
comparison to non-Indigenous Australians. Notably,
these differences were seen despite the Indigenous co-
hort being, on average, younger than the non-
Indigenous cohort which suggests early onset of PAD
in this population. This may be due to earlier onset
of PAD risk factors, such as diabetes, in Indigenous
Australians [7]. It may also reflect greater prevalence
of other risk factors for PAD in this population. Indi-
genous Australians had significantly higher smoking
rates which is consistent with large observational
studies [7]. Smoking is a strong risk factor for PAD,
[20] and results from the Freemantle Diabetes Study







Intermittent Claudication 8 (50.0%) 126 (32.7%)
Critical Limb Ischemia 2 (12.5%) 24 (6.2%)
Abdominal Aortic or peripheral aneurysm 3 (18.8%) 142 (36.9%)
Asymptomatic carotid stenosis 2 (12.5%) 46 (11.9%)
Symptomatic carotid stenosis 1 (6.2%) 47 (12.2%)
aIndicates predominant presentation. Some patients had both lower limb symptoms and abdominal aortic aneurysm
Fig. 1 Kaplan-Meier curve illustrating the cumulative proportion of
Indigenous and non-Indigenous patients with PAD, who had a major
cardiovascular event (MI or stroke or death). CV, cardiovascular. Differences
between both groups compared using the log-rank test (p= 0.004). The
green line represents patients who were Indigenous, and the pink line
represents non-Indigenous Australians. Vertical lines represent participants
who were censored during follow-up
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suggested that although smoking rates amongst non-
Indigenous Australians has almost halved over the
past 15 years, smoking rates have remained relatively
unchanged in Indigenous Australians [7].
As with Australian data, previously published re-
search in other countries focused on Indigenous pop-
ulations has mainly looked at lower limb
amputations secondary to diabetes-associated foot
disease and cardiovascular events in patients that
have diabetes [21–23]. It is therefore difficult to
compare our findings to those reported regarding
other Indigenous populations. In a retrospective ana-
lysis of Canadian Aboriginal and non-Aboriginal sub-
jects with PAD, Aboriginal patients had a
significantly higher prevalence of risk factors for PAD
such as diabetes, hypertension, and renal failure, al-
though Aboriginal ethnicity did not have an inde-
pendent association with mortality [24]. A more
comprehensive understanding of the epidemiology
and outcome of PAD amongst different populations
is warranted, given the high morbidity and mortality
associated with this condition. In addition to differ-
ences in cardiovascular risk factors between Indigen-
ous and non-Indigenous populations, previous studies
have suggested that specific populations may have a
predisposition to develop a particular anatomical dis-
tribution of arterial disease, which may contribute to
poor clinical outcomes [25]. For example, in a retro-
spective analysis of 1215 PAD patients, the preva-
lence of aorto-iliac and infra-geniculate disease was
higher in African-American and Asian populations
compared to the Caucasian population [26–28]. In
the current study, Indigenous Australians had more
frequent lower limb presentations (intermittent clau-
dication and critical limb ischemia) compared to
non-Indigenous Australians, although differences
were not significant. It is not yet clear whether these
differences are related to ethnicity or rather clinical
risk factors associated with distal PAD, such as dia-
betes [29].
This study has several limitations. Although our re-
quired sample size of 230 patients was exceeded, the
recruited patients were unevenly distributed between
the Indigenous and non-Indigenous groups (1:24).
This is likely to have underpowered our study to de-
tect significant differences in some established PAD
risk factors and presenting complaints between Indi-
genous and non-Indigenous Australians. Although a
significant association between Indigenous Australians
with PAD and major cardiovascular events was estab-
lished, confidence intervals were wide, which is re-
flective of the limited sample size, and it is possible
that the true magnitude of the effect size may be dif-
ferent. Furthermore, data on important cardiovascular
risk factors such as body mass index, glycaemic con-
trol, ankle brachial index and blood pressure were
not collected. We only recruited participants from
the outpatient setting, and were unable to include pa-
tients with emergency presentations, which may be of
significance to Indigenous populations given greater
rates and severity of diabetes and higher prevalence
of complicating factors such as sepsis [30].
Conclusion
Placing our results in the context of what was previ-
ously known, this study highlights a significant health
gap for Indigenous Australian patients with PAD. In-
digenous Australians presented with PAD at a youn-
ger age, and were at significantly greater risk of major
cardiovascular events compared to non-Indigenous
Australians. They also more commonly had cardiovas-
cular risk factors such as current smoking and
insulin-treated diabetes, emphasising the need for
more intensive management of modifiable risk factors
in this population. Further study in this area with lar-
ger sample sizes is required to further characterise
the excess burden of PAD in the Indigenous popula-
tion, which may help identify additional clinical tar-
gets for improving PAD outcome.
Table 3 Cox proportional hazard analyses for the association between Indigenous ethnicity and combined incidence of major
cardiovascular events (MI, stroke or death) in PAD patients
Unadjusted HR (95%CI) p-value Adjusted HR (95%CI) p-value
MI, stroke or death
Non-Indigenous 1.00 – 1.00 –
Indigenous 3.59 (1.42–9.07) 0.007 3.12 (1.14–8.49) 0.026 a
– – 4.03 (1.17–13.84) 0.027 b
– – 4.72 (1.41–15.78) 0.012 c
MI myocardial infarction, CI confidence interval, HR hazard ratio, IHD ischemic heart disease, ACE angiotensin converting enzyme
aResults are adjusted for hypertension, current smoking, diabetes, IHD, and age
bResults are adjusted for hypertension, current smoking, diabetes, IHD, age, insulin and frusemide prescription
cResults are adjusted for hypertension, current smoking, diabetes, IHD, age, insulin, frusemide, ACE inhibitor, anti-platelet or anti-coagulant prescription and critical
limb ischemia
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